A team of researchers has developed a new gene therapy for children with Dravet syndrome, a rare type of epilepsy in children ...

Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with ...

Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...

Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet ...

Author:  Brad Chapman, Head of U.S. Epilepsy and Rare Syndromes, UCB | Hear from UCB’s Brad Chapman on the importance of ...

Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...

At this time, I would like to welcome everyone to Harmony Biosciences fourth quarter and full-year 2024 financial results ...

The drug is the first non-cannabinoid option for patients with LGS and an alternative to Jazz Pharma's Epidyolex (cannabidiol ...

A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri ...

New life-changing treatment option fenfluramine recommended for type of rare epilepsy, Lennox–Gastaut syndrome ...

Starting today, the National Institute for Health and Care Excellence (NICE) has recommended the funding of fenfluramine for ...